Insight

Jill Feldman: A few thoughts on Update from phase 3 MARIPOSA trial in EGFR NSCLC

Jill Feldman/henryford.com

Jan 8, 2025, 10:02

Jill Feldman: A few thoughts on Update from phase 3 MARIPOSA trial in EGFR NSCLC

Jill Feldman, Co-Founder of EGFR Resisters and Lung cancer Patient and Advocate, shared her recent article on X:

“Update from phase 3 MARIPOSA trial in EGFR NSCLC shows statistically significant improvement in OS. “The median overall survival improvement expected to exceed 1 year”

A few thoughts:

– 1 year is meaningful to patients, making SDM critical so patients/families can make informed decisions
– Mitigating AE’s is also critical (ie steroids upfront) I look forward to seeing COCOON data (enhanced derm support upfront) & the approval of SQ
– Need to see subgroup analysis to be able to stratify patients better

The true value of research to patients and families is HOPE. Thank you, JNJ Innovation, for giving people HOPE and for being open to honest feedback in order to take steps to make the patient experience better.”

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board.

Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.